Cargando…
From Immunogen to COVID-19 vaccines: Prospects for the post-pandemic era
The COVID-19 pandemic has affected millions of people and posed an unprecedented burden on healthcare systems and economies worldwide since the outbreak of the COVID-19. A considerable number of nations have investigated COVID-19 and proposed a series of prevention and treatment strategies thus far....
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Author(s). Published by Elsevier Masson SAS.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9805901/ https://www.ncbi.nlm.nih.gov/pubmed/36800265 http://dx.doi.org/10.1016/j.biopha.2022.114208 |
_version_ | 1784862422095364096 |
---|---|
author | Miao, Ganggang Chen, Zhiqiang Cao, Hengsong Wu, Wenhao Chu, Xi Liu, Hanyuan Zhang, Leyao Zhu, Hongfei Cai, Hongzhou Lu, Xiaolan Shi, Junfeng Liu, Yuan Feng, Tingting |
author_facet | Miao, Ganggang Chen, Zhiqiang Cao, Hengsong Wu, Wenhao Chu, Xi Liu, Hanyuan Zhang, Leyao Zhu, Hongfei Cai, Hongzhou Lu, Xiaolan Shi, Junfeng Liu, Yuan Feng, Tingting |
author_sort | Miao, Ganggang |
collection | PubMed |
description | The COVID-19 pandemic has affected millions of people and posed an unprecedented burden on healthcare systems and economies worldwide since the outbreak of the COVID-19. A considerable number of nations have investigated COVID-19 and proposed a series of prevention and treatment strategies thus far. The pandemic prevention strategies implemented in China have suggested that the spread of COVID-19 can be effectively reduced by restricting large-scale gathering, developing community-scale nucleic acid testing, and conducting epidemiological investigations, whereas sporadic cases have always been identified in numerous places. Currently, there is still no decisive therapy for COVID-19 or related complications. The development of COVID-19 vaccines has raised the hope for mitigating this pandemic based on the intercross immunity induced by COVID-19. Thus far, several types of COVID-19 vaccines have been developed and released to into financial markets. From the perspective of vaccine use in globe, COVID-19 vaccines are beneficial to mitigate the pandemic, whereas the relative adverse events have been reported progressively. This is a review about the development, challenges and prospects of COVID-19 vaccines, and it can provide more insights into all aspects of the vaccines. |
format | Online Article Text |
id | pubmed-9805901 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | The Author(s). Published by Elsevier Masson SAS. |
record_format | MEDLINE/PubMed |
spelling | pubmed-98059012023-01-04 From Immunogen to COVID-19 vaccines: Prospects for the post-pandemic era Miao, Ganggang Chen, Zhiqiang Cao, Hengsong Wu, Wenhao Chu, Xi Liu, Hanyuan Zhang, Leyao Zhu, Hongfei Cai, Hongzhou Lu, Xiaolan Shi, Junfeng Liu, Yuan Feng, Tingting Biomed Pharmacother Review The COVID-19 pandemic has affected millions of people and posed an unprecedented burden on healthcare systems and economies worldwide since the outbreak of the COVID-19. A considerable number of nations have investigated COVID-19 and proposed a series of prevention and treatment strategies thus far. The pandemic prevention strategies implemented in China have suggested that the spread of COVID-19 can be effectively reduced by restricting large-scale gathering, developing community-scale nucleic acid testing, and conducting epidemiological investigations, whereas sporadic cases have always been identified in numerous places. Currently, there is still no decisive therapy for COVID-19 or related complications. The development of COVID-19 vaccines has raised the hope for mitigating this pandemic based on the intercross immunity induced by COVID-19. Thus far, several types of COVID-19 vaccines have been developed and released to into financial markets. From the perspective of vaccine use in globe, COVID-19 vaccines are beneficial to mitigate the pandemic, whereas the relative adverse events have been reported progressively. This is a review about the development, challenges and prospects of COVID-19 vaccines, and it can provide more insights into all aspects of the vaccines. The Author(s). Published by Elsevier Masson SAS. 2023-02 2023-01-02 /pmc/articles/PMC9805901/ /pubmed/36800265 http://dx.doi.org/10.1016/j.biopha.2022.114208 Text en © 2023 The Authors Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Review Miao, Ganggang Chen, Zhiqiang Cao, Hengsong Wu, Wenhao Chu, Xi Liu, Hanyuan Zhang, Leyao Zhu, Hongfei Cai, Hongzhou Lu, Xiaolan Shi, Junfeng Liu, Yuan Feng, Tingting From Immunogen to COVID-19 vaccines: Prospects for the post-pandemic era |
title | From Immunogen to COVID-19 vaccines: Prospects for the post-pandemic era |
title_full | From Immunogen to COVID-19 vaccines: Prospects for the post-pandemic era |
title_fullStr | From Immunogen to COVID-19 vaccines: Prospects for the post-pandemic era |
title_full_unstemmed | From Immunogen to COVID-19 vaccines: Prospects for the post-pandemic era |
title_short | From Immunogen to COVID-19 vaccines: Prospects for the post-pandemic era |
title_sort | from immunogen to covid-19 vaccines: prospects for the post-pandemic era |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9805901/ https://www.ncbi.nlm.nih.gov/pubmed/36800265 http://dx.doi.org/10.1016/j.biopha.2022.114208 |
work_keys_str_mv | AT miaoganggang fromimmunogentocovid19vaccinesprospectsforthepostpandemicera AT chenzhiqiang fromimmunogentocovid19vaccinesprospectsforthepostpandemicera AT caohengsong fromimmunogentocovid19vaccinesprospectsforthepostpandemicera AT wuwenhao fromimmunogentocovid19vaccinesprospectsforthepostpandemicera AT chuxi fromimmunogentocovid19vaccinesprospectsforthepostpandemicera AT liuhanyuan fromimmunogentocovid19vaccinesprospectsforthepostpandemicera AT zhangleyao fromimmunogentocovid19vaccinesprospectsforthepostpandemicera AT zhuhongfei fromimmunogentocovid19vaccinesprospectsforthepostpandemicera AT caihongzhou fromimmunogentocovid19vaccinesprospectsforthepostpandemicera AT luxiaolan fromimmunogentocovid19vaccinesprospectsforthepostpandemicera AT shijunfeng fromimmunogentocovid19vaccinesprospectsforthepostpandemicera AT liuyuan fromimmunogentocovid19vaccinesprospectsforthepostpandemicera AT fengtingting fromimmunogentocovid19vaccinesprospectsforthepostpandemicera |